ArticleFrontiers in public health2025
Utilization of upper gastrointestinal tumor inpatient services affected by COVID-19 in China 2018-2021: an interrupted time series analysis.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The COVID-19 pandemic has posed an unprecedented challenge to the healthcare system addressing chronic diseases, significantly affecting inpatient healthcare access. We aimed to determine the impact of COVID-19 on inpatient healthcare utilization for patients with upper gastrointestinal (UGI) tumors, which would help improve responses to medical healthcare needs under future public health emergencies. Method: Utilizing interrupted time-series analysis (ITSA), we analyzed data of UGI tumor patients from 37 medical institutions in Yangzhou from 2018 to 2021. Data were extracted from the Yangzhou City Health Information Platform in Jiangsu Province, and key indicators for analysis included demographics, clinical characteristics, and hospitalization utilization (length of hospital stay, hospital costs). The intervention point was set at January 2020, marking the onset of COVID-19. Result: Seven thousand three hundred and two cases were included in the analysis. The hospital days and total hospitalization costs decreased instantaneously by 1.60 (95%CI: -2.69, -0.51) days and 5349.04 (95%CI: -11015.66, 317.571) Yuan, respectively. During the post-pandemic period, hospital days and expenses surged, exceeding pre-pandemic levels by late 2021. The structure of medical costs has changed, with the cost of blood and consumables increasing by 345.53 (95%CI: 176.07, 514.99) Yuan and 755.23 (95%CI: -698.96, 2209.42) Yuan, respectively, at the time of the outbreak. Self-payment expense increased by 1150.77 (95%CI: -243.36,2544.91) Yuan, and reimbursement ratios slightly decreased by 0.03 (95%CI: -0.11, 0.05). Additionally, significant changes occurred in the occupational structure, health insurance utilization, and complication status of patients hospitalized with UGI tumors during the pandemic. Conclusion: Our findings indicate that the outbreak did cause a reduction in the use of UGI tumor inpatient services in Yangzhou City. The COVID-19 pandemic exacerbated the disease burden among patients with UGI tumors, with significantly increased costs for blood products and consumables. The findings emphasize the need to strengthen emergency management, implement precise prevention and control measures based on the dynamics of the epidemic, and ensure the safe supply of blood products and emergency medical supplies. It is necessary to improve the primary healthcare institution system to ensure patients' access to medical services. The COVID-19 pandemic may exacerbate health inequalities. Therefore, it is essential to optimize the medical insurance system, provide targeted subsidies to medical institutions, curb the growth of unreasonable medical costs, and offer special protection for vulnerable groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.